Bioatla Inc (BCAB)

Currency in USD
0.353
-0.027(-7.11%)
Closed·
After Hours
0.376+0.024(+6.72%)
·
BCAB Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Unusual Post-Market activity
BCAB is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.3420.389
52 wk Range
0.2402.525
Key Statistics
Prev. Close
0.38
Open
0.366
Day's Range
0.342-0.389
52 wk Range
0.24-2.525
Volume
510.9K
Average Volume (3m)
598.98K
1-Year Change
-75.99%
Book Value / Share
-0.29
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BCAB Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
8.333
Upside
+2,260.72%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year

Bioatla Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Bioatla Inc Company Profile

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company’s lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and squamous cell carcinoma of head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.

Bioatla Inc SWOT Analysis


Pivotal Pipeline
Explore BioAtla's clinical-stage oncology portfolio, featuring promising CAB therapies for solid tumors, with key data readouts expected in 2025
Financial Strategy
Delve into BioAtla's cost management efforts and strategic workforce reduction, extending cash runway into 2026 amid clinical development challenges
Market Positioning
Learn how BioAtla's innovative CAB platform differentiates it in the competitive oncology landscape, balancing potential against established rivals
Investor Outlook
Analyst price targets range from $1 to $5, reflecting both risks and potential upside as BioAtla approaches critical clinical and partnership milestones
Read full SWOT analysis

Bioatla Inc Earnings Call Summary for Q1/2025

  • Bioatla reported Q1 2025 EPS of -$0.26, beating expectations of -$0.39, despite an 8.19% stock drop in aftermarket trading
  • Net loss reduced to $15.3M from $23.2M YoY, driven by decreased R&D and G&A expenses, reflecting strategic cost management
  • Clinical trials show promising results for cancer treatments using the company's Dual Conditionally Active Biologic (CAD) platform
  • Company forecasts continued R&D expense reductions in 2025 and key clinical readouts by H1 2026, with FY2025 EPS projected at -$1.13
  • Analysts maintain a bullish stance with a consensus recommendation of 1.75, despite ongoing challenges and competitive pressures
Last Updated: 06/05/2025, 22:16
Read Full Transcript

Compare BCAB to Peers and Sector

Metrics to compare
BCAB
Peers
Sector
Relationship
P/E Ratio
−0.3x−1.5x−0.5x
PEG Ratio
−0.01−0.030.00
Price/Book
−1.2x1.7x2.6x
Price / LTM Sales
1.9x9.5x3.3x
Upside (Analyst Target)
-319.3%43.5%
Fair Value Upside
Unlock6.6%6.8%Unlock

Analyst Ratings

3 Buy
1 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 8.333
(+2,260.72% Upside)

Earnings

Latest Release
Aug 07, 2025
EPS / Forecast
-0.32 / -0.26
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

BCAB Income Statement

People Also Watch

2.070
VOR
0.00%
0.984
GAME
+1.76%
0.380
ADIL
-1.81%
9.070
CAPR
+12.39%
0.2320
PCSA
+0.39%

FAQ

What Stock Exchange Does Bioatla Trade On?

Bioatla is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Bioatla?

The stock symbol for Bioatla is "BCAB."

What Is the Bioatla Market Cap?

As of today, Bioatla market cap is 20.60M.

What Is Bioatla's Earnings Per Share (TTM)?

The Bioatla EPS (TTM) is -1.11.

When Is the Next Bioatla Earnings Date?

Bioatla will release its next earnings report on 04 Nov 2025.

From a Technical Analysis Perspective, Is BCAB a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Bioatla Stock Split?

Bioatla has split 0 times.

How Many Employees Does Bioatla Have?

Bioatla has 61 employees.

What is the current trading status of Bioatla (BCAB)?

As of 09 Aug 2025, Bioatla (BCAB) is trading at a price of 0.35, with a previous close of 0.38. The stock has fluctuated within a day range of 0.34 to 0.39, while its 52-week range spans from 0.24 to 2.53.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.